Anonymous #3 3w

Investing in yourself is playing the long game 💪

11

Anonymous #1 3w

Right bc wtf

1

Anonymous yakinaway 3w

Biotech. High risk stuff. Got a potential epi pen replacement making up most of the recent gains at about ~32k since May. Expecting another 10k minimum on that between now and January but I have a lot of shares. Other than that the typical over pumped ai tech garbage that I’m actively selling. I can drop a couple tickers if you’re interested but you’re probably too late for most of it

2

Anonymous yakinaway 3w

Aqst probably a sure $8 per share by early January. Approval of epinephrine film set for on or before January 31st. Advise selling early if you decide to try to hop on that. Iovance is my next biotech play but it could very easily flop. They have the first ever approved TIL cancer treatment. Currently only being used on solid melanoma as a second-line treatment for stage 4 metastatic patients. I believe ORR was 49% but do your own research. It’s essentially a custom cancer treatment

2

Anonymous yakinaway 3w

Cancer research is where big buyout premium potential occurs. The TIL therapy requires them to remove a sample from the patient and within 30 days they develop a custom treatment built from the patient’s body. There is evidence that healthier, early stage patients have higher success but research is still underway. It’s also extremely expensive before insurance and there are company/leadership concerns with profitability. They’re researching application for lung cancer as well.

2